Cardiomyocyte-like cells (CMs) derived from human pluripotent stem cells (hPSCs) present a valuable model for human disease modeling, studying early human development and, potentially, developing cell therapeutic approaches. However, the specification of early hPSC-derived CMs into defined cardiac subtypes such as atrial and ventricular cells is not well understood and, thus, poorly controlled. Moreover, the maturation status of hPSC-CMs is not well defined, yet it is known that these cells undergo at least some degree of maturation upon longer term in vitro culture. To gain insight into this process, and to assess their developmental status, we have recently generated a data set of hPSC-CMs monitoring global changes in gene expression upon long term maintenance in vitro, in comparison to human atrial and ventricular heart samples (GEO accession number GEO: GSE64189). These data present a rich resource for evaluating the maturation status of hPSC-CMs, for identifying suitable markers for subtype-specific gene expression, as well as for the generation of functional hypotheses. Here, we provide additional details and quality checks of this data set, and exemplify how it can be used to identify maturation-associated as well as cardiac subtype-specific markers.
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Experimental Design, Materials and Methods

Generation and processing of samples
Cell culture. hPSCs, cell line FS3F.2 [1] , were maintained in FTDA medium [2] , on Matrigel™-coated dishes. Cardiac differentiation was induced as described [3] . In brief, fully confluent hPSC cultures were harvested using Accutase™ digestion, and replated onto Matrigelcoated 24-well plates (500,000 cells per well in 2 ml of day 0 differentiation medium). An aliquot of cells was used for RNA isolation (0 week time-point). Day 0 differentiation medium contained Knockout™ DMEM, insulin/transferrin/selenium, 10 μM Y27632, penicillin/streptomycin/L-Glutamine, 10 ng/ml FGF2, 1 ng/ml BMP4, and 1 μM CHIR99021 [3] . Day 1 medium contained Knockout™ DMEM transferrin/selenium penicillin/streptomycin/L-Glutamine, and 250 μM phospho-ascorbate (TS medium). On days 2 and 3, cells were fed with 
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Genomics Data j o u r n a l h o m e p a g e : h t t p : / / w w w . j o u r n a l s . e l s e v i e r . c o m / g e n o m i c s -d a t a / TS medium supplemented with 2 μM of WNT inhibitor IWP-2. Hence after, cells were maintained in basal TS medium. Spontaneous beating was observed from day 6 onwards. CM differentiation efficiency was above 85% as judged by FACS counting [3] . On day 7, the cells were harvested using 1× TrypLE Select (Life Technologies), and pooled from independent samples. An aliquot of cells was used for RNA isolation (1 week time-point), and the remaining cells replated at~250,000 cells per well of a Matrigel-coated 24-well plate, in 2% fetal calf serum/ Knockout DMEM/penicillin/streptomycin/L-Glutamine. Thereafter, medium was replaced every 3-4 days. Samples of maturating hPSC-CMs were taken at weekly intervals up to 8 weeks, to be subjected to microarray analysis. Total RNA was isolated using Qiagen RNeasy columns with on-column DNA digestion.
Human heart samples. RNA samples from left and right atrial appendages have been previously described [4] . RNA samples were pooled from six independent patients per tissue type. The human left and right ventricular RNA samples were from a commercial supplier (Biocat #R1234138-50-BC and #R1234139-50-BC, respectively). 500 ng of total RNA from each biological sample was used as input for the generation of biotin-labeled cRNA using an Illumina® TotalPrep™ RNA amplification kit (Life Technologies). Following the manufacturer's instructions, in vitro transcription of double-stranded cDNA was performed for 14 h, in a PCR cycler. Purified biotin-labeled cRNA was eluted in a volume of 100 μl and quality-checked on a 2100 Bioanalyzer device (Agilent Technologies). cRNA samples were adjusted to 150 ng/μl in water, and hybridized onto Illumina HumanHT-12 v4 bead arrays following the manufacturer's instructions throughout. Hybridization was carried out at 58°C for 18 h. Staining with streptavidin-Cy3 (GE Healthcare #PA43001) was carried out as recommended, at a concentration 1 μg/ml in blocking buffer. Dried bead arrays were scanned on a HiScan SQ device (Illumina) using default settings.
Technical and biological data quality assessment
Scanned images were confirmed to show an overall clean fluorescence spot morphology with high signal-to-noise ratio, and array data were confirmed to display an average P 95 intensity of N800 (a.u.). Inspection of raw data in GenomeStudio suggested an overall high hybridization stringency, according to internal mismatch control probes, and no major hybridization artifacts. Following these routine checks, all separately hybridized samples were background-subtracted and normalized using the Cubic Spline algorithm in GenomeStudio. This revealed a high degree of similarity between the left/right human heart samples, suggesting that they could be combined in silico. To assess overall human heart-specific gene expression regardless of chamber-specific differences, data was additionally analyzed by combining all human atrial and ventricular samples using GenomeStudio software.
As a biological quality control step, known markers were used to assess differential gene expression between the distinct types of samples. In line with the expectations, hPSC-specific genes OCT4, NANOG and SOX2 were only expressed in the undifferentiated (0 week) cells. Conversely, structural cardiac markers (MYH6, MYL4, MYL7) were indeed only expressed in the differentiated samples and not in the undifferentiated cells (Fig. 1A, left) . Focusing on gene expression changes upon long-term in vitro culture, maturation markers such as MYL2 and MYH7 were upregulated in the late (8 weeks) samples, whereas markers of immature hPSC-CMs were indeed overrepresented in the early (1 week) samples (Fig. 1A, middle) . As supported by functional assays [3] , however, there were only marginal differences between 4 weeks and 8 week-old hPSC-CMs, suggesting that the cells reach a rather stable transcriptomic state from approximately 4 weeks onwards (Fig. 1A, right) . Furthermore, the expression pattern of the pan-cardiac marker ACTC1 (cardiac muscle alpha actin) served to indicate an overall stable cardiomyocyte signature in all differentiated samples (1 to 8 weeks, Fig. 1B) . 
Basic data analysis
A comparison of human atrial and ventricular samples allowed for the identification of marker genes. Using stringent filtering criteria (N10-fold differences in gene expression), these included known structural genes, ion channels, as well as transcriptional regulators (Fig. 2, Table 1 ). For instance, myosin light chain 2 (MYL2, also known as MLC2v) presents a rather stringent ventricular marker. By contrast, the frequently used MYL7 (MLC2a) was only about 2-fold enriched in atrial tissue, suggesting that it does not well discriminate between human cardiac subtypes. Instead, the natriuretic peptide-encoding genes NPPA and NPPB are excellent atrial markers according to this analysis.
Analyzing the hPSC-based together with the in vivo data allows determination of shared and divergent gene expression between hPSCCMs and human heart. In line with the expectations, scatter plot and clustering analyses between human heart versus (i) undifferentiated hPSCs, (ii) early (1 week) hPSC-CMs, and (iii) maturated hPSC-CMs (combined 4-8 weeks samples) suggest that over time, hPSC-CMs tend to become more similar to the human adult heart reference (Fig. 3 ). This tendency is also supported by the fact that a set of known immature CM markers (NKX2.5, IRX4, and others) declines upon long-term in vitro culture, whereas a set of maturation marker genes (MYH7, MYL2, and others) reached human heart-like expression levels over time (blue and orange colored genes, respectively, in Fig. 3 ). However, even in late hPSC-CMs a number of human heart genes were not expressed, and the global similarity to the in vivo reference appears to be rather limited (red colored genes in Fig. 3 , Table 2 ).
Discussion
Despite the fact that neither the in vitro-derived nor the in vivo samples consisted of pure populations of cardiomyocytes, this data set suggests that meaningful biological information can be extracted from it. The combined hPSC-CM/adult human heart data hence presents a useful resource for evaluating the maturation status of hPSC-CMs at the transcriptional level as well as for assessing cardiac subtype-specific gene expression. Notably, according to our analysis, the frequently used MYL7 (MLC2a) gene appears to be unsuited for discriminating between atrial and ventricular subtypes. Our data instead suggests alternative genes, such as NPPA and NPPB, as being well-suited markers for evaluating atrial subtype specification in hPSC-CMs. 
